Immix Biopharma, Inc. IMMX Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s finance lease right of use asset amortization?
- Immix Biopharma, Inc. (IMMX) reported finance lease right of use asset amortization of $39.19K in Q1 2026.
- How has Immix Biopharma, Inc.'s finance lease right of use asset amortization changed year-over-year?
- Immix Biopharma, Inc.'s finance lease right of use asset amortization increased by 86.4% year-over-year, from $21.03K to $39.19K.
- What does finance lease right of use asset amortization mean?
- This represents the non-cash expense recognized over the lease term for the right-of-use asset associated with finance leases. It reflects the systematic allocation of the asset's cost to the income statement, impacting operating cash flow adjustments. Monitoring this helps investors understand the company's reliance on leased capital assets versus direct ownership.